<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116931</url>
  </required_header>
  <id_info>
    <org_study_id>011</org_study_id>
    <nct_id>NCT04116931</nct_id>
  </id_info>
  <brief_title>Switch From Ticagrelor to Clopidogrel in ACS Patients After PCI</brief_title>
  <acronym>SWITCH</acronym>
  <official_title>A Randomized Controlled Trial on the Switch From Ticagrelor to Clopidogrel in ACS Patients After PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, open-label clinical trial which will enroll 80 acute
      coronary syndrome (ACS) patients after Percutaneous Transluminal Coronary Intervention (PCI)
      in China. Patients on maintenance dosing (MD) of aspirin (100 mg/d) and ticagrelor (90 mg
      twice daily) will be divided into two groups switching from ongoing ticagrelor to clopidogrel
      600 mg loading dose (LD)/ 75 mg MD according to their bleeding risk. Then each group will
      randomly switch at different times(24 hours/ 12 hours after the last MD of ticagrelor).
      Pharmacodynamic assessments are performed at baseline, and at 4h, 8h, 24h, 48h, 72h hours
      with platelet aggregation rate by Light Transmittance Aggregometry method (LTA). All patients
      are followed-up for 30 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of the study was platelet inhibition measured by Light Transmittance
      Aggregometry method(LTA). Secondary clinical endpoints included a 30-day major adverse
      cardiovascular endpoint (MACE) defined as a composite of cardiovascular death, recurrent
      myocardial infarction, target vessel revascularisation or stroke and individual components of
      the MACE. Safety endpoints of 30-day TIMI major and minor bleed were also evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of platelet aggregation between different time points</measure>
    <time_frame>baseline,4 hours,8 hours,24 hours,48 hours,72 hours</time_frame>
    <description>Regional differences between blood samples from each subjects of different groups by LTA.The results of LTA are reported in platelet aggregation rate(%).Platelet aggregation was induced by0.5mg/ml arachidonic acid (AA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical endpoint event</measure>
    <time_frame>30 days</time_frame>
    <description>Secondary clinical endpoints included a 30-day major adverse cardiovascular endpoint (MACE) defined as a composite of cardiovascular death, recurrent myocardial infarction, target vessel revascularisation or stroke and individual components of the MACE. Safety endpoints of 30-day TIMI major and minor bleed were also evaluated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <arm_group>
    <arm_group_label>clopidogrel-600 mg-12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clopidogrel 600 mg loading dose (LD) 12 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel-600 mg-24h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clopidogrel 600 mg loading dose (LD) 24 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel-75 mg-12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clopidogrel 75 mg maintenance dose(MD) 12 hours after the last MD of ticagrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel-75 mg-24h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clopidogrel 75 mg maintenance dose（MD) 24 hours after the last MD of ticagrelor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch ticagrelor to clopidogrel</intervention_name>
    <description>Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor</description>
    <arm_group_label>clopidogrel-600 mg-12h</arm_group_label>
    <arm_group_label>clopidogrel-600 mg-24h</arm_group_label>
    <arm_group_label>clopidogrel-75 mg-12h</arm_group_label>
    <arm_group_label>clopidogrel-75 mg-24h</arm_group_label>
    <other_name>switch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years.

          -  ACS patients.

          -  Patients who are treated with ticagrelor and do not tolerate it.

          -  Volunteer to participate and sign informed consent.

          -  Approved by national regulatory authorities ethics committees.

        Exclusion Criteria:

          -  Patients who are contraindicated, intolerant or resistant to clopidogrel.

          -  History of hematological disease or bleeding tendency; platelet count &lt; 100 × 10^9
             cells/L, or &gt; 600 × 10^9 cells/L, hemoglobin &lt; 100 g/L.

          -  Abnormal liver or kidney function (ALT &gt; 3 ULN; estimated CrCl &lt; 30 ml/min calculated
             by Cockcroft-Gault equation); diagnosed severe pulmonary disease.

          -  Patients in need of drugs which affect the efficacy of clopidogrel such as miconazole,
             ketoconazole, andfluconazole.

          -  Malignancies or other comorbid conditions with life expectancy less than 1 year.

          -  Pregnant or lactating woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunjian Li, Dr, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunjian Li, Dr, PhD</last_name>
    <phone>+86-13701465229</phone>
    <email>drcjli@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qian Gu</last_name>
    <phone>+86-18351972592</phone>
    <email>Solsticeg@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuming Zhang, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Chai, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Dr., MD, Ph.D, Director of CCU Ward</investigator_title>
  </responsible_party>
  <keyword>Dual antiplatelet therapy (DAPT)</keyword>
  <keyword>Platelet function</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Switch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

